Neuberger Berman Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Neuberger Berman Group’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-115	Closed	-$86K	–	1758
2017 Q4	$86K	Hold	115	–	–	﹤0.01%	1735
2017 Q3	$33K	Hold	115	–	–	﹤0.01%	1592
2017 Q2	$30K	Hold	115	–	–	﹤0.01%	1583
2017 Q1	$38K	Hold	115	–	–	﹤0.01%	1581
2016 Q4	$69K	Hold	115	–	–	﹤0.01%	1576
2016 Q3	$131K	Hold	115	–	–	﹤0.01%	1549
2016 Q2	$127K	Hold	115	–	–	﹤0.01%	1500
2016 Q1	$148K	Hold	115	–	–	﹤0.01%	1448
2015 Q4	$284K	Buy	+115	New	+$177K	﹤0.01%	1389

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Neuberger Berman Group's NBSE Position: Q1 2018 in Review

Neuberger Berman Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 115 shares — an estimated $86K sold.

Neuberger Berman Group first reported a position in NBSE in Q4 2015 and held it in 9 quarters. The position peaked at $284K in Q4 2015. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

Neuberger Berman Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Neuberger Berman Group sold 115 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $86K.
Neuberger Berman Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2015 and held it in 9 quarters.
Neuberger Berman Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $284K in Q4 2015.
35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Neuberger Berman Group's 13F filing for Q1 2018, filed 8 May 2018.